Company Name
Sichuan Omnis Pharmaceutical Co., Ltd.
Year of Establishment
2005
Enterprise Size
more than 1000
Annual Turnover(USD)
More than 99,999,999
Company Introduction
A leading pharmaceutical company engaged in R&D, manufacturing and marketing of high quality medicinal products with special focus on CVS/CNS areas. Our manufacturing sites comply with EU/FDA/China GMP.
Ginkgolide injection is a global innovative herbal medicinal product of its kind for treatment of mild-moderate cerebral infarction. Other generic products are Enoxaparin sodium injection, pantoprazole sodium for injection, etc. Over 20 generic drugs are under development.
We also provide contract manufacture service of liquid injectables, lyophilized, tablets and capsules and cooperate with firms to introduce high-end pharmaceutical products into Chinese market.Baiyu are open to any business cooperation that can bring benefits to both sides.
In 2020, Baiyu Medical Supplies is founded and provide high quality of Personal Protective Equipment to again COVID-19, and relevant products(KN95, Disposable Medical mask, FFP3, FFP2, Type IIR) have launched around the whole world.
Main Competitive Advantages
International Approvals/Standards,Experienced R&D Staff,Delivery Term,Production Capacity,Large Product Line,Contract Manufacturing (CRO,CMO),Small Orders Accepted,Reputation,Quality Service,
Website
http://www.baiyu.cn
Other Competitive Advantages
Chengdu Baiyu Pharmaceutical Co., Ltd
High quality-CDMO trusted partner
Our 4 Factories
•#1 Wenjiang •104667㎡
•#2 Wenjiang •20000㎡
•#3 Yuechi •130000㎡
•#4 CDHT •53333㎡
Quality by Design——
Focusing on the conception of "intelligent, economic and sustainable” , we hired experienced talents from Germany designed manufacturing facilities for, pursuing internationally accredited manufacturing system that meets the requirements of US FDA, EMA, and NMPA.
Intelligent management with automatic production, digitized process
Baiyu provide CDMO service for:
FDFs & APIs
Primary & secondary packaging
Warehousing
Commercial scale, pilot scale, laboratory scale
You are warmly welcomed to contact us for business cooperation.
CDMO Service Undertaking:
Dosage Form Production Lines Annual Capacity
Injection 8 650,000,000
Oral Solid 3 700,000,000
API & Intermediates 3 8,000 Kg
TCM Extraction 2 5,000,000 Kg
Patents and Copyright
Ginkgolide injection
Milestone
2019
Obtained the second EU Marketing Authorization
2018
February,Ginkgolide Pharmaceutical(GKL) has obtained GMP certification
March,GKL obtained approval certification for injectables
March, Obtained the first EU Marketing Authorization
2017
June, Ginkgolide injection was covered by national health insurance
2016
November, listed on the NEEQ
September, completed the phase Ⅱ construction of Gkinkgolide base
2015
Completed the phase Ⅰ construction of Ginkgolide base
Enoxaparin launched in market
Shares reforms for stock market
2014
Wenjiang Plant upgraded, meeting the requirements of new GMP
Construction of Ginkgolide factory started
Lansoprazole and Pantoprazole launched in market
2013
Founded Ginkgolide Pharmaceutical Co., Ltd and began to build manufacturing base complies with cGMP
2012
Ginkgolide Injection launched in market
November, founded Sunshine Ginkgo Agriculture Development Co., Ltd.
2011
Founded Chengdu Golden Ginkgo Pharmaceutical Co., Ltd,pass the site inspection of Ginkgo Injection.
October, Ginkgolide Injection received the new drug certificate
November, commercial production of Ginkgolide Injection
2009
March, obtained GMP certification of small volume injectables
September, obtained GMP certification of freeze-dried powder
November, started to manufacture freeze-dried powder and injectables and launched in market
2008
First experts panel of Ginkgolide injection
2005
Founded Baiyu Technology Pharmaceutical Co., Ltd.
1999
Started research and development of Ginkgolide injection;
Obtained the second EU Marketing Authorization
2018
February,Ginkgolide Pharmaceutical(GKL) has obtained GMP certification
March,GKL obtained approval certification for injectables
March, Obtained the first EU Marketing Authorization
2017
June, Ginkgolide injection was covered by national health insurance
2016
November, listed on the NEEQ
September, completed the phase Ⅱ construction of Gkinkgolide base
2015
Completed the phase Ⅰ construction of Ginkgolide base
Enoxaparin launched in market
Shares reforms for stock market
1999
Started research and development of Ginkgolide injection;